Arthur Levinson Net Worth

What is Arthur Levinson's Net Worth and Salary?

Arthur Levinson is an American biochemist, biotech pioneer, and corporate executive who has a net worth of $1.7 billion.

Arthur Levinson has played a uniquely influential role at the intersection of Silicon Valley and the pharmaceutical industry. Best known for his long tenure as CEO of Genentech and as a key board member and chairman of Apple Inc., Levinson has spent decades shaping both modern medicine and consumer technology. A rare figure who successfully transitioned from laboratory scientist to top-tier executive, he helped transform Genentech into one of the world's leading biotech companies while also serving as a trusted advisor to Steve Jobs during Apple's most pivotal years. At Apple, Levinson became one of the longest-tenured and most powerful insiders, eventually rising to Chairman of the Board following Jobs's death. He has also remained active in cutting-edge scientific research as the founder and CEO of Calico, an ambitious longevity-focused company backed by Alphabet Inc.. Known for his quiet authority, deep technical expertise, and long-term thinking, Levinson is widely regarded as one of the most respected figures in both biotech and big tech.

Early Life and Education

Arthur D. Levinson was born on March 31, 1950, in Seattle, Washington. From an early age, he was drawn to science, particularly the molecular mechanisms that govern life. He pursued this interest academically, earning a Bachelor of Science in molecular biology from the University of Washington in 1972.

He continued his education at Princeton University, where he earned a Ph.D. in biochemistry in 1977. Following graduate school, Levinson completed a postdoctoral fellowship at the University of California, San Francisco. There, he worked under renowned scientists J. Michael Bishop and Harold Varmus, both of whom would later receive the Nobel Prize.

During this period, Levinson contributed to groundbreaking research, including the discovery that the viral src oncogene encodes a protein kinase. This marked one of the first times an enzymatic function was identified in a tumor-causing gene, a major milestone in cancer biology.

Building Genentech and the Rise of Biotech

In 1980, Levinson joined Genentech, one of the earliest biotechnology startups, as a research scientist. At the time, the company was pioneering the use of genetic engineering to develop new medicines. Levinson quickly distinguished himself through both scientific innovation and leadership.

One of his most important contributions was improving the company's ability to manufacture complex biological drugs. He helped engineer Chinese Hamster Ovary (CHO) cells to act as efficient "protein factories," a breakthrough that became a standard technique across the biotech industry.

Unlike many executives, Levinson continued working in the lab even as he climbed the corporate ladder. He was promoted to Vice President of Research Technology in 1989 and Senior Vice President of Research and Development in 1993. In 1995, he became CEO.

As chief executive, Levinson cultivated a culture that blended academic research with commercial discipline. Scientists were encouraged to pursue independent projects alongside company priorities, a structure that helped fuel innovation. Under his leadership, Genentech developed several groundbreaking therapies, including Herceptin, a major advance in breast cancer treatment.

Levinson remained CEO until 2009, guiding the company through rapid growth and ultimately its full acquisition by Roche. By the time he stepped down, Genentech had become one of the most important biotech companies in the world.

Role at Apple and Relationship with Steve Jobs

Levinson joined Apple's Board of Directors in August 2000, becoming one of the key figures behind the scenes during the company's modern resurgence. Over the years, he developed a close personal and professional relationship with Steve Jobs.

When Jobs was diagnosed with pancreatic cancer in 2003, Levinson was among the first people he consulted. Their relationship extended beyond business, with Levinson serving as both a scientific advisor and trusted confidant.

After Jobs's death in 2011, Apple's board selected Levinson to serve as non-executive Chairman. In this role, he helped guide the company through its transition into the Tim Cook era, providing continuity and strategic oversight during a period of massive growth.

Levinson has been one of the longest-serving members of Apple's board and one of its most influential insiders, helping shape decisions at the highest level of the company.

Getty Images

Boardroom Influence and Industry Crossroads

At one point, Levinson held board seats at both Apple and Google, reflecting his status as a highly sought-after advisor in the tech industry. However, as competition intensified between Apple's iPhone and Google's Android platform, this dual role became untenable.

In 2009, amid regulatory scrutiny and concerns over conflicts of interest, Levinson resigned from Google's board to remain with Apple. The move underscored both his importance to Apple and the growing rivalry between the two companies.

Throughout his board career, Levinson has been known for his measured, analytical approach, bringing a scientist's mindset to complex business decisions.

Calico and the Pursuit of Longevity

In 2013, Levinson returned more directly to scientific research when he was recruited by Alphabet to found and lead Calico, short for California Life Company. The venture was created with an ambitious goal: to better understand aging and develop treatments for age-related diseases.

As CEO of Calico, Levinson has overseen long-term research initiatives that blend biology, data science, and advanced therapeutics. The company operates with a level of patience and funding rarely seen in biotech, allowing it to pursue high-risk, high-reward scientific breakthroughs.

This role reflects Levinson's enduring commitment to science and his belief that some of the most important problems in medicine require decades of sustained effort.

Compensation, Stock Holdings, and Wealth

In addition to his executive roles, Levinson has accumulated substantial wealth through his long association with Apple. As one of the company's longest-serving board members, he has received significant stock-based compensation over time.

As of early 2026, Levinson beneficially owns approximately 4.1 million shares of Apple stock, making him one of the company's largest individual insider shareholders. This stake is larger than that of many top executives, including Tim Cook, and is valued at roughly $1 billion depending on market conditions.

Like most corporate insiders, Levinson has periodically sold shares through structured trading plans for diversification and tax purposes. Even so, his holdings remain substantial, reflecting both his longevity at Apple and the company's extraordinary growth over the past two decades.

Leadership Transition and Continuing Influence

As Apple continues to evolve, Levinson's role has also shifted. Following the company's leadership transition in 2026, he is expected to move from Chairman to Lead Independent Director, while Tim Cook transitions to Executive Chairman.

Despite this change, Levinson remains a central figure in Apple's governance, providing continuity, institutional knowledge, and strategic guidance.

Across biotech and technology, Arthur Levinson's career stands out for its rare combination of scientific achievement and corporate leadership. Whether advancing cancer research, guiding one of the world's most valuable companies, or pursuing breakthroughs in longevity, he has consistently operated at the highest levels of both science and business.

Who's Richer?

Arthur
Levinson

Compare!

Tim
Cook